What are HIF prolyl hydroxylase inhibitor drugs?

HIF prolyl hydroxylase inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting Prolyl hydroxylase (PHD)). 0 are currently marketed, with 4 more in clinical development.

HIF prolyl hydroxylase inhibitor

0 marketed 4 in Phase 3

This page covers all HIF prolyl hydroxylase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Prolyl hydroxylase (PHD), Hypoxia-inducible factor prolyl hydroxylase (HIF-PH), Prolyl hydroxylase domain-containing proteins (PHD).

Targets

Prolyl hydroxylase (PHD) · Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) · Prolyl hydroxylase domain-containing proteins (PHD)

Phase 3 pipeline (4)

Daprodustat large · GlaxoSmithKline · Hematology / Nephrology
Daprodustat is a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that stabilizes HIF to increase endogenous erythropoietin production and boost red blood cell formation.
Daprodustat tablets · GlaxoSmithKline · Hematology / Nephrology
Daprodustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that stimulates endogenous erythropoietin production to treat anemia.
Daprodustat (GSK1278863) · GlaxoSmithKline · Hematology
Daprodustat inhibits hypoxia-inducible factor prolyl hydroxylase (HIF-PH), stabilizing HIF and increasing endogenous erythropoietin production to treat anemia.
Daprodustat small · GlaxoSmithKline · Hematology / Nephrology
Daprodustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that stabilizes HIF to increase endogenous erythropoietin production and boost red blood cell formation.